# OnCo record prostate-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/roadmaps/prostate-roadmap/>
  a schema:CreativeWork ;
  onco:kind "roadmap" ;
  schema:identifier "prostate-roadmap" ;
  schema:name "Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch"@en ;
  schema:alternateName "Prostate cancer history"@en, "Prostate cancer evidence roadmap"@en, "History of prostate cancer treatment"@en, "Prostate cancer timeline"@en ;
  schema:description "Prostate cancer is where hormone therapy for cancer was invented, in 1941, and where a blood test created an epidemic of diagnoses forty-five years later. This roadmap follows the evidence from castration to the modern androgen receptor drugs, through the screening trials and the argument about overdiagnosis they started, to DNA repair, PSMA and the questions still open in 2032."@en ;
  schema:url <https://onco.cc/roadmaps/prostate-roadmap/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://www.cancer.gov/types/prostate>, <https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-genitourinary-cancers/prostate-cancer>, <https://uroweb.org/guidelines/prostate-cancer>, <https://clinicaltrials.gov/study/NCT06320067> ;
  onco:status "active" ;
  onco:related <https://onco.cc/roadmaps/hormonal-therapy-roadmap/>, <https://onco.cc/roadmaps/early-detection-roadmap/>, <https://onco.cc/roadmaps/targeted-therapy-roadmap/>, <https://onco.cc/roadmaps/radiopharma-roadmap/>, <https://onco.cc/roadmaps/molecular-imaging-roadmap/>, <https://onco.cc/roadmaps/surgery-roadmap/>, <https://onco.cc/roadmaps/chemotherapy-roadmap/>, <https://onco.cc/roadmaps/immunotherapy-roadmap/>, <https://onco.cc/roadmaps/diagnostics-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-low-risk/>, <https://onco.cc/cancers/prostate-intermediate-risk/>, <https://onco.cc/cancers/prostate-high-risk/>, <https://onco.cc/cancers/prostate-bcr/>, <https://onco.cc/cancers/prostate-mhspc/>, <https://onco.cc/cancers/prostate-nmcrpc/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-nepc/> ;
  onco:sections <https://onco.cc/fronts/hormonal/>, <https://onco.cc/fronts/early-detection/>, <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/radiopharma/>, <https://onco.cc/fronts/surgery/>, <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/imaging/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-overdiagnosis/>, <https://onco.cc/bottlenecks/b-early-detection/>, <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-hereditary-risk/>, <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-global-access/>, <https://onco.cc/bottlenecks/b-survivorship/> .